Phase 2 Study of NGM282 in Patients With Type 2 Diabetes
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Alex M DePaoli, MD
NGM Biopharmaceuticals, Inc
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ngm Clinical Study Site 6103
Melbourne, Victoria, Australia
- Ngm Clinical Study Site 6104
Melbourne, Victoria, Australia
- Ngm Clinical Study Site 6101
Perth, Western Australia, Australia
- Ngm Clinical Study Site 6403
Auckland, New Zealand
- Ngm Clinical Study Site 6405
Auckland, New Zealand
- Ngm Clinical Study Site 6401
Christchurch, New Zealand
- Ngm Clinical Study Site 6406
Dunedin, New Zealand
- Ngm Clinical Study Site 6404
Tauranga, New Zealand
- Ngm Clinical Study Site 6402
Wellington, New Zealand
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2013
- Primary completion
- 30 Sept 2014
- Completion
- 30 Sept 2014
- Last update posted
- 17 Nov 2015
- Registered enrollment
- 81
- Registry id
- NCT01943045
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.